Medison Pharma

Morris C. Laster serves as Founder and Chairman of Medison Pharma. The firm is family-controlled, and investment decisions are likely overseen by a combination of the Laster family and senior management, though specific CIO or CEO roles are not publicly named.

Medison sources deals through direct relationships with biotech firms seeking market access outside their home regions. The firm's track record in regulatory approval and commercialization in Israel, China, and other markets acts as a differentiator, attracting partners who need a reliable local partner.

Medison Pharma is first a pharmaceutical commercialization and distribution company, family-owned by the Laster family. It incorporates an investment arm that takes equity and milestone-based positions in partner biotechs, making it a hybrid entity rather than a pure family office or venture capital firm.

Medison focuses on late-stage therapeutics—drugs that have completed or are nearing completion of clinical trials and have regulatory approval in at least one major market. The firm avoids early-stage R&D risk, instead specializing in commercial execution.

Medison does not publicly state excluded sectors, but by its nature it avoids medical devices, diagnostics, and early-stage discovery biotech. Its focus is on approved or near-approved pharmaceutical products, primarily in oncology, rare disease, and specialty therapeutics.

The wealth originated from the pharmaceutical distribution and commercialization business built by Morris C. Laster since 1995. The firm reinvests profits from commercial operations into new partnerships and equity stakes.

Public records indicate the Laster family operates a charitable foundation, but details are sparse. The foundation is legally separate from Medison Pharma's commercial operations, though both are controlled by the family.